477 related articles for article (PubMed ID: 26037900)
1. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of the Age-Adjusted Charlson Comorbidity Index (ACCI) on Short- and Long-Term Outcome in Patients with Advanced Primary Epithelial Ovarian Cancer.
Kahl A; du Bois A; Harter P; Prader S; Schneider S; Heitz F; Traut A; Alesina PF; Meier B; Walz M; Brueckner A; Groeben HT; Brunkhorst V; Heikaus S; Ataseven B
Ann Surg Oncol; 2017 Nov; 24(12):3692-3699. PubMed ID: 28871563
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of the age-adjusted Charlston co-morbidity index on peri-operative complications, adjuvant chemotherapy usage and survival in patients undergoing debulking surgery after neo-adjuvant chemotherapy for advanced epithelial ovarian cancer.
Phillips A; Singh K; Pounds R; Sundar S; Kehoe S; Nevin J; Elattar A; Balega J
J Obstet Gynaecol; 2017 Nov; 37(8):1070-1075. PubMed ID: 28741395
[TBL] [Abstract][Full Text] [Related]
4. Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
Tseng JH; Cowan RA; Afonso AM; Zhou Q; Iasonos A; Ali N; Thompson E; Sonoda Y; O'Cearbhaill RE; Chi DS; Abu-Rustum NR; Long Roche K
Gynecol Oncol; 2018 Nov; 151(2):287-293. PubMed ID: 30185381
[TBL] [Abstract][Full Text] [Related]
5. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
6. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Chi DS; Musa F; Dao F; Zivanovic O; Sonoda Y; Leitao MM; Levine DA; Gardner GJ; Abu-Rustum NR; Barakat RR
Gynecol Oncol; 2012 Jan; 124(1):10-4. PubMed ID: 21917306
[TBL] [Abstract][Full Text] [Related]
7. Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Gynecol Oncol; 2018 Aug; 150(2):233-238. PubMed ID: 29933927
[TBL] [Abstract][Full Text] [Related]
8. Incidence of and risk factors for postoperative ileus in women undergoing primary staging and debulking for epithelial ovarian carcinoma.
Bakkum-Gamez JN; Langstraat CL; Martin JR; Lemens MA; Weaver AL; Allensworth S; Dowdy SC; Cliby WA; Gostout BS; Podratz KC
Gynecol Oncol; 2012 Jun; 125(3):614-20. PubMed ID: 22370599
[TBL] [Abstract][Full Text] [Related]
9. Recurrence patterns of advanced ovarian, fallopian tube, and peritoneal cancers after complete cytoreduction during interval debulking surgery.
Usami T; Kato K; Taniguchi T; Abe A; Nomura H; Yamamoto A; Matoda M; Okamoto S; Kondo E; Omatsu K; Kawamata Y; Takeshima N
Int J Gynecol Cancer; 2014 Jul; 24(6):991-6. PubMed ID: 24905612
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of video laparoscopic surgical debulking of recurrent ovarian, fallopian tube, and primary peritoneal cancers.
Nezhat FR; Denoble SM; Cho JE; Brown DN; Soto E; Chuang L; Gretz H; Saharia P
JSLS; 2012; 16(4):511-8. PubMed ID: 23484556
[TBL] [Abstract][Full Text] [Related]
11. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
12. Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers.
Minaguchi T; Satoh T; Matsumoto K; Sakurai M; Ochi H; Onuki M; Oki A; Yoshikawa H
Int J Clin Oncol; 2016 Jun; 21(3):573-9. PubMed ID: 26475355
[TBL] [Abstract][Full Text] [Related]
13. The impact of ultra-radical surgery in the management of patients with stage IIIC and IV epithelial ovarian, fallopian tube, and peritoneal cancer.
Turnbull HL; Akrivos N; Wemyss-Holden S; Maiya B; Duncan TJ; Nieto JJ; Burbos N
Arch Gynecol Obstet; 2017 Mar; 295(3):681-687. PubMed ID: 27995370
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer.
Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC
Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454
[TBL] [Abstract][Full Text] [Related]
15. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study.
Rungruang B; Miller A; Richard SD; Hamilton CA; Rodriguez N; Bookman MA; Maxwell GL; Krivak TC; Horowitz NS
Gynecol Oncol; 2012 Jan; 124(1):53-8. PubMed ID: 22032836
[TBL] [Abstract][Full Text] [Related]
16. Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type.
Toptas T; Pestereli E; Erol O; Bozkurt S; Erdogan G; Simsek T
Int J Gynecol Cancer; 2016 Jul; 26(6):1012-9. PubMed ID: 27206284
[TBL] [Abstract][Full Text] [Related]
17. Introduction of staging laparoscopy in the management of advanced epithelial ovarian, tubal and peritoneal cancer: impact on prognosis in a single institution experience.
Fagotti A; Vizzielli G; Fanfani F; Costantini B; Ferrandina G; Gallotta V; Gueli Alletti S; Tortorella L; Scambia G
Gynecol Oncol; 2013 Nov; 131(2):341-6. PubMed ID: 23938372
[TBL] [Abstract][Full Text] [Related]
18. The shift toward neo-adjuvant chemotherapy and interval debulking surgery for management of advanced ovarian and related cancers in a population-based setting: Impact on clinical outcomes.
Nicklin JL; McGrath S; Tripcony L; Garrett A; Land R; Tang A; Perrin L; Chetty N; Jagasia N; Crandon AJ; Nascimento M; Walker G; Sanday K; Obermair A
Aust N Z J Obstet Gynaecol; 2017 Dec; 57(6):651-658. PubMed ID: 28718942
[TBL] [Abstract][Full Text] [Related]
19. Success rate and safety of tumor debulking with diaphragmatic surgery for advanced epithelial ovarian cancer and peritoneal cancer.
Saitou M; Iida Y; Komazaki H; Narui C; Matsuno K; Kawabata A; Ueda K; Tanabe H; Takakura S; Isonishi S; Sasaki H; Okamoto A
Arch Gynecol Obstet; 2015 Mar; 291(3):641-6. PubMed ID: 25182215
[TBL] [Abstract][Full Text] [Related]
20. Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.
Phippen NT; Barnett JC; Lowery WJ; Miller CR; Leath CA
Gynecol Oncol; 2013 Oct; 131(1):158-62. PubMed ID: 23872110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
